Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include: Genu varum, Bowing of the legs, and Osteochondritis dissecans.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Bones and joints | 1 | Osteochondritis dissecans |
Biomarker and diagnostic research for Blount disease, adolescent has been reported in the published literature.
No clinical trials have been registered for Blount disease, adolescent.
13 publications have been identified in PubMed for Blount disease, adolescent. Research spans Clinical Trial Publication (46%), Review / Meta-Analysis (15%), and Basic Science / Preclinical (15%).
Research Type | Count | % of Total |
|---|---|---|
Clinical study results | 6 | 46% |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 1:01 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about Blount disease, adolescent
2 |
15% |
Laboratory research | 2 | 15% |
Disease patterns and progression | 2 | 15% |
Testing and diagnosis research | 1 | 8% |
Tageldeen Mohamed M (2026). [PMID: 41347460](https://pubmed.ncbi.nlm.nih.gov/41347460/). *J Pediatr Orthop*. [Clinical Trial Publication]
Coskun E (2026). [PMID: 41178588](https://pubmed.ncbi.nlm.nih.gov/41178588/). *J Pediatr Orthop*. [Clinical Trial Publication]
Jansen N (2026). [PMID: 41523661](https://pubmed.ncbi.nlm.nih.gov/41523661/). *JB JS Open Access*. [Epidemiology / Natural History]
Kim Y (2025). [PMID: 39461587](https://pubmed.ncbi.nlm.nih.gov/39461587/). *Orthop Traumatol Surg Res*. [Clinical Trial Publication]
Feijoo E (2025). [PMID: 40162483](https://pubmed.ncbi.nlm.nih.gov/40162483/). *J Pediatr Orthop*. [Epidemiology / Natural History]
Hussein MA (2025). [PMID: 40963115](https://pubmed.ncbi.nlm.nih.gov/40963115/). *J Orthop Surg Res*. [Clinical Trial Publication]
Galal S (2025). [PMID: 40816413](https://pubmed.ncbi.nlm.nih.gov/40816413/). *Orthop Traumatol Surg Res*. [Basic Science / Preclinical]
Makarov MR (2025). [PMID: 40823474](https://pubmed.ncbi.nlm.nih.gov/40823474/). *JB JS Open Access*. [Diagnostic / Biomarker]
Wang B (2025). [PMID: 40270720](https://pubmed.ncbi.nlm.nih.gov/40270720/). *Front Endocrinol (Lausanne)*. [Review / Meta-Analysis]
Shim JW (2024). [PMID: 39618518](https://pubmed.ncbi.nlm.nih.gov/39618518/). *Clin Orthop Surg*. [Basic Science / Preclinical]
AI-curated news mentioning Blount disease, adolescent
Updated Jul 8, 2026
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration. In a press release on Wednesday, the FDA announced it had approved Casgevy, the first gene therapy for children with sickle cell disease. (NewsNation) — A new treatment for children aged 2 or older with sickle cell disease has been approved by the Food & Drug Administration (FDA). In a Wednesday news release, the FDA announced it had approved Casgevy, the first gene therapy for children with the disease. “Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion,” the release noted. “Pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” Karim Mikhail, the acting director of the Center for Biologics Evaluation and Research, wrote. “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” Megha Kaushal, acting deputy director of the Office of Therapeutic Products in CBER, said in the release.